Compare Funko Inc (FNKO) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Nuvalent Inc — how do they compare? Funko Inc trades at $5.78 (market cap $315.21M), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 31.1× Funko Inc's market cap. Which is the better fit depends on your goals.
| FNKO | NUVL | |
|---|---|---|
Market Cap | $315.21M | $9.81B |
Sector | Consumer Staples | Technology |
52-Week High | $5.88 | $123.96 |
52-Week Low | $2.46 | $72.16 |
Enterprise Value | $560.25M | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $5.785, up 4.23% today, with a bullish technical signal from moving averages. The stock shows improving revenue trends, with Q1 2026 sales reaching $200.9M, beating expectations, though net income remains negative. Analyst consensus is split between Buy and Hold, with no Sell ratings. Recent news highlights new product launches and strong collectibles demand, supporting a positive sentiment shift.
Outlook: FNKO presents a speculative opportunity with recent earnings beats and revenue growth, but risks include persistent net losses and high debt. Investors should weigh the bullish technicals and product momentum against fundamental weaknesses in profitability and cash flow volatility.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a P/B ratio of 8.35 and negative profitability metrics. The stock is technically bullish based on moving averages, though oscillators are neutral. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, announced on June 9, 2026 (Reuters). Earnings have been mixed, with two misses and one beat in the last three quarters.
The acquisition by GSK provides a near-term price floor but limits upside. Risks include ongoing financial losses and shareholder litigation questioning deal fairness. Analyst sentiment is mixed with 42% buy ratings. The stock's outlook hinges on deal completion, with fundamental challenges persisting until closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
